# Phase 2 Primary Myelofibrosis trials recruiting: 26 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials in phase 2 for Primary Myelofibrosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Primary Myelofibrosis trials: 26 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/primary-myelofibrosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 26
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07938580 | Gecacitinib Plus Luspatercept in Patients With Myelofibrosis and Anemia | Peking Union Medical College Hospital | Phase 2 | Not yet recruiting | Myelofibrosis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938580) |
| November 13, 2026 | NCT07936201 | Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia | Case Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Myelofibrosis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936201) |
| October 14, 2026 | NCT07872709 | Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872709) |
| August 6, 2026 | NCT07750574 | Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis | Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 2 | Not yet recruiting | Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750574) |
| April 24, 2026 | NCT07551427 | A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk... | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | Myelofibrosis | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551427) |
| March 13, 2026 | NCT07471503 | Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Myelofibrosis (MF), HSCT | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471503) |
| March 4, 2026 | NCT07447817 | Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias | Sponsor not shown (see the record) | Phase 2 | Recruiting | Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07447817) |
| February 20, 2026 | NCT07424950 | Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis | United Lincolnshire Hospitals NHS Trust | Phase 2 | Not yet recruiting | Myelofibrosis | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424950) |
| February 6, 2026 | NCT07394153 | Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia | Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | Phase 2 | Recruiting | Myelofibrosis，MF | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07394153) |
| November 14, 2025 | NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic... | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07228624) |
| March 5, 2025 | NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With... | Center for International Blood and Marrow Transplant Research | Phase 2 | Recruiting | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic... | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859424) |
| January 13, 2025 | NCT06770842 | Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis | The University of Hong Kong | Phase 2 | Recruiting | Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06770842) |
| October 28, 2024 | NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | National Cancer Institute (NCI) | Phase 2 | Recruiting | Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06661915) |
| August 7, 2024 | NCT06541249 | MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial | Icahn School of Medicine at Mount Sinai | Phase 2 | Recruiting | Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF) | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06541249) |
| July 24, 2024 | NCT06517875 | Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis | GlaxoSmithKline | Phase 2 | Recruiting | Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential... | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06517875) |
| April 3, 2024 | NCT06345495 | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Splenomegaly, Myelofibrosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06345495) |
| October 2, 2023 | NCT06063486 | Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic... | University of Southern California | Phase 2 | Recruiting | Clonal Cytopenia of Undetermined Significance, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelofibrosis... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06063486) |
| September 28, 2023 | NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1... | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06059391) |
| August 8, 2023 | NCT05980806 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | Karyopharm Therapeutics Inc | Phase 2 | Recruiting | Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05980806) |
| April 28, 2023 | NCT05835466 | Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Icahn School of Medicine at Mount Sinai | Phase 2 | Recruiting | Myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (ET-MF), Post Polycythemia Vera Related Myelofibrosis... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05835466) |
| April 10, 2023 | NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia... | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05805605) |
| September 8, 2021 | NCT05037760 | A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis | Takeda | Phase 2 | Recruiting | Myelofibrosis | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05037760) |
| May 17, 2021 | NCT04888741 | Methods of T Cell Depletion Trial (MoTD) | University of Birmingham | Phase 2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04888741) |
| April 30, 2020 | NCT04370301 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Primary Myelofibrosis, Secondary Myelofibrosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04370301) |
| February 24, 2020 | NCT04282187 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | University of Washington | Phase 2 | Recruiting | Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04282187) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Masonic Cancer Center, University of Minnesota | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Icahn School of Medicine at Mount Sinai | 2 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 1 |
| [Chengdu Zenitar Biomedical Technology Co., Ltd](https://specstream.ai/data/clinical-trials/company/chengdu-zenitar-biomedical-technology-co-ltd) | 1 |
| University of Birmingham | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| City of Hope Medical Center | 1 |
| The University of Hong Kong | 1 |
| [Karyopharm Therapeutics Inc](https://specstream.ai/data/clinical-trials/company/karyopharm-therapeutics-inc) | 1 |
| Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | 1 |
| National Cancer Institute (NCI) | 1 |
| Peking Union Medical College Hospital | 1 |
| University of Southern California | 1 |
| University of Washington | 1 |
| Case Comprehensive Cancer Center | 1 |
| M.D. Anderson Cancer Center | 1 |
| United Lincolnshire Hospitals NHS Trust | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 17 |
| Spain | 4 |
| France | 3 |
| Italy | 3 |
| United Kingdom | 3 |
| South Korea | 2 |
| Canada | 2 |
| Germany | 2 |
| Australia | 1 |
| Brazil | 1 |
| Hong Kong | 1 |
| Belgium | 1 |
| Bulgaria | 1 |
| Czechia | 1 |
| Denmark | 1 |
| Greece | 1 |
| Hungary | 1 |
| Israel | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Romania | 1 |
| Taiwan | 1 |
| China | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Dominican restaurants in the United States](https://specstream.ai/data/businesses/dominican-restaurants/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
- [Bed and breakfasts in the United States](https://specstream.ai/data/businesses/bed-and-breakfasts/united-states)
- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
- [Water delivery companies in the United States](https://specstream.ai/data/businesses/water-delivery-companies/united-states)
- [Fireplace services in the United States](https://specstream.ai/data/businesses/fireplace-services/united-states)
